New lipid-lowering drugs - The Scientist - Magazine of the Life SciencesTudor TomaThe ScientistScientist
All at sea: new lipid-lowering drug trials continue to disappoint. Int J Clin Pract. 2013;67:595–8.A. S., Wierzbicki. (2013) All at sea: new lipid-lowering drug trials continue to disappoint. International Journal of Clinical Practice 67 , 595-598 /...
The objectives of this study were to (1) describe the sociodemographic, psychosocial, and health characteristics of clients with dementia (relative to two control subgroups) from a population-based home care cohort; and, (2) determine the distribution and associated characteristics of cholinesterase ...
To investigate whether lipid-lowering drugs are associated with new-onset diabetes after adjusting for baseline clinical risk factors for diabetes. A retrospective cohort study. Japanese employees of large corporations and their dependents using health insurance claims data linked to clinical and laboratory...
Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia Type II a and Type II bFirst clinical results are presented for two newly developed drugs. Both are diphenylmethane derivatives named ethyl... C Najemnik,H Lageder,H Regal,... - Arzneimittel-Fors...
This marks the first approval in the US for the novel PCSK-9 class of drugs for use in patients with hypercholesterolemia or high CV risk. It also comes just hours after a European regulatory body recommended the drug be approved.
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are the most effective and best-tolerated drugs to treat elevated levels of low-density lipoprotein cholesterol (LDL-C). In addition, they exhibit other effects unrelated to their lipid lowering effects (pleiotropic ...
Statins, often hailed as a “wonder drug,” are a class of lipid-lowering medications that significantly reduce cholesterol levels in the blood. These drugs inhibit the enzyme HMG-CoA reductase, which plays a crucial role in the production of cholesterol in the liver. By lowering cholesterol, ...
By targeting different types of lipid metabolic disorders, the use of different lipid-lowering drugs is a new treatment approach for metabolic OA. Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which can effectively lower serum cholesterol levels and...
In recent years, with the extensive research on the pathological mechanism and molecular mechanism of DKD, there are more and more new drugs based on this, such as new hypoglycemic drugs sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) inhibitors, and ...